Brief: Lantern Pharma Receives FDA Clearance Of IND Application For LP-184
12/06/2023 15:08
June 12 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA RECEIVES FDA CLEARANCE OF IND APPLICATION
FOR
DRUG CANDIDATE LP-184 IN SOLID TUMORS
* LANTERN PHARMA INC - FIRST-IN-HUMAN PHASE 1A TRIAL FOR
LP-184 IS
ANTICIPATED TO LAUNCH AND DOSE ITS FIRST PATIENT DURING CURRENT
QUARTER
Source text for Eikon: ID:nBw3Kd67qa
Further company coverage: LTRN.O
(reuters.briefs@thomsonreuters.com)
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments